Coherus Biosciences Holds Virtual Annual Stockholder Meeting

An announcement from Coherus Biosciences ( (CHRS) ) is now available.

On June 11, 2025, Coherus Oncology, Inc. held its Annual Meeting of Stockholders virtually, where various proposals were voted on. The stockholders elected three Class II directors, ratified Ernst & Young LLP as the company’s accounting firm, approved executive compensation, and amended the 2014 Employee Stock Purchase Plan.

The most recent analyst rating on (CHRS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.

Spark’s Take on CHRS Stock

According to Spark, TipRanks’ AI Analyst, CHRS is a Neutral.

The overall stock score reflects significant financial challenges, including declining revenues and high leverage, which are major risk factors. While there are promising growth prospects from the oncology focus and recent corporate events, the technical analysis indicates bearish trends. The valuation remains unattractive due to negative earnings and lack of dividends. Strategic initiatives and cost-saving measures offer some positive outlook, but financial stability and market penetration remain crucial.

To see Spark’s full report on CHRS stock, click here.

More about Coherus Biosciences

Coherus Oncology, Inc. operates in the biotechnology industry, focusing on the development and commercialization of oncology therapeutics.

Average Trading Volume: 1,702,604

Technical Sentiment Signal: Strong Sell

Current Market Cap: $93.31M

See more insights into CHRS stock on TipRanks’ Stock Analysis page.